Cartesian Therapeutics, Inc. Operating Lease Cost
Cartesian Therapeutics, Inc. (RNAC) reported Operating Lease Cost of $569.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Cartesian Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $569.00K, a 0.35% decline year-over-year.
- Cartesian Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $583.00K, a 0.17% decline year-over-year.
- Cartesian Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $575.00K, a 46.11% decline year-over-year.
- Cartesian Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $557.00K, a 47.35% decline year-over-year.
- Cartesian Therapeutics, Inc. operating lease, cost for fiscal 2025 was $2.29M, a 40.69% decline from fiscal 2024.
- Cartesian Therapeutics, Inc. operating lease, cost for fiscal 2024 was $3.86M, a 36.35% increase from fiscal 2023.
- Cartesian Therapeutics, Inc. operating lease, cost for fiscal 2023 was $2.83M, a 24.25% increase from fiscal 2022.
- Cartesian Therapeutics, Inc. operating lease, cost for fiscal 2022 was $2.28M, a 12.51% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $569.00K 10-Q · filed 2026-08-06 | $1.15M 10-Q · filed 2026-08-06 | $1.73M derived: sum of 3 quarters · filed 2026-08-06 | $2.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $583.00K 10-Q · filed 2026-04-30 | $1.16M derived: sum of 2 quarters · filed 2026-04-30 | $1.72M derived: sum of 3 quarters · filed 2026-04-30 | $2.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.13M derived: sum of 2 quarters · filed 2026-03-09 | $1.70M derived: sum of 3 quarters · filed 2026-08-06 | $2.29M 10-K · filed 2026-03-09 |
| 2025-09-30 | $557.00K 10-Q · filed 2025-11-06 | $1.13M derived: sum of 2 quarters · filed 2026-08-06 | $1.71M 10-Q · filed 2025-11-06 | $2.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $571.00K 10-Q · filed 2026-08-06 | $1.16M 10-Q · filed 2026-08-06 | $2.22M derived: sum of 3 quarters · filed 2026-08-06 | $3.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $584.00K 10-Q · filed 2026-04-30 | $1.65M derived: sum of 2 quarters · filed 2026-04-30 | $2.71M derived: sum of 3 quarters · filed 2026-04-30 | $3.67M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.13M derived: sum of 2 quarters · filed 2026-03-09 | $3.08M derived: sum of 3 quarters · filed 2026-03-09 | $3.86M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.06M 10-Q · filed 2025-11-06 | $2.01M derived: sum of 2 quarters · filed 2025-11-06 | $2.79M 10-Q · filed 2025-11-06 | $3.53M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $956.00K 10-Q · filed 2025-08-07 | $1.73M 10-Q · filed 2025-08-07 | $2.47M derived: sum of 3 quarters · filed 2025-08-07 | $3.17M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $775.00K 10-Q · filed 2025-05-08 | $1.51M derived: sum of 2 quarters · filed 2025-05-08 | $2.21M derived: sum of 3 quarters · filed 2025-05-08 | $2.91M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $740.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.44M derived: sum of 2 quarters · filed 2025-03-13 | $2.13M derived: sum of 3 quarters · filed 2025-03-13 | $2.83M 10-K · filed 2025-03-13 |
| 2023-09-30 | $696.00K 10-Q · filed 2024-11-07 | $1.39M derived: sum of 2 quarters · filed 2024-11-07 | $2.09M 10-Q · filed 2024-11-07 | $2.78M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $696.00K 10-Q · filed 2024-08-08 | $1.39M 10-Q · filed 2024-08-08 | $2.09M derived: sum of 3 quarters · filed 2024-08-08 | $2.66M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $696.00K 10-Q · filed 2024-05-08 | $1.39M derived: sum of 2 quarters · filed 2024-05-08 | $1.96M derived: sum of 3 quarters · filed 2024-05-08 | $2.47M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $696.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.26M derived: sum of 2 quarters · filed 2024-03-07 | $1.77M derived: sum of 3 quarters · filed 2024-03-07 | $2.28M 10-K · filed 2024-03-07 |
| 2022-09-30 | $569.00K 10-Q · filed 2023-11-13 | $1.07M derived: sum of 2 quarters · filed 2023-11-13 | $1.58M 10-Q · filed 2023-11-13 | $2.25M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $505.00K 10-Q · filed 2023-08-17 | $1.01M 10-Q · filed 2023-08-17 | $1.68M derived: sum of 3 quarters · filed 2024-03-07 | $2.14M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $506.00K 10-Q · filed 2023-05-04 | $1.17M derived: sum of 2 quarters · filed 2024-03-07 | $1.63M derived: sum of 3 quarters · filed 2024-03-07 | $2.08M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.13M derived: sum of 2 quarters · filed 2024-03-07 | $1.58M derived: sum of 3 quarters · filed 2024-03-07 | $2.02M 10-K · filed 2024-03-07 |
| 2021-09-30 | $457.00K 10-Q · filed 2022-11-03 | $911.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.35M 10-Q · filed 2022-11-03 | $1.86M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $454.00K 10-Q · filed 2022-08-08 | $898.00K 10-Q · filed 2022-08-08 | $1.40M derived: sum of 3 quarters · filed 2023-03-02 | $1.91M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $444.00K 10-Q · filed 2022-05-05 | $950.00K derived: sum of 2 quarters · filed 2023-03-02 | $1.46M derived: sum of 3 quarters · filed 2023-03-02 | $2.07M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $506.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.01M derived: sum of 2 quarters · filed 2023-03-02 | $1.63M derived: sum of 3 quarters · filed 2023-03-02 | $2.10M 10-K · filed 2023-03-02 |
| 2020-09-30 | $506.00K 10-Q · filed 2021-11-09 | $1.12M derived: sum of 2 quarters · filed 2021-11-09 | $1.59M 10-Q · filed 2021-11-09 | $1.93M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $613.00K 10-Q · filed 2021-08-12 | $1.08M 10-Q · filed 2021-08-12 | $1.43M derived: sum of 3 quarters · filed 2022-03-10 | $1.77M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $472.00K 10-Q · filed 2021-05-13 | $814.00K derived: sum of 2 quarters · filed 2022-03-10 | $1.16M derived: sum of 3 quarters · filed 2022-03-10 | $1.50M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $683.00K derived: sum of 2 quarters · filed 2022-03-10 | $1.02M derived: sum of 3 quarters · filed 2022-03-10 | $1.36M 10-K · filed 2022-03-10 |
| 2019-09-30 | $341.00K 10-Q · filed 2020-11-05 | $682.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.02M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $341.00K 10-Q · filed 2020-08-06 | $682.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $341.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |